Salirasib

Salirasib is a Ras inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.

Product Specifications

CAS Number

[162520-00-5]

Product Name Alternative

S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; FTS

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; Ras

Type

Reference compound

Related Pathways

Autophagy; GPCR/G Protein; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Salirasib.html

Purity

99.04

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C(O)C1=CC=CC=C1SC/C=C(C)/CC/C=C(C)/CC/C=C(C)/C

Molecular Formula

C22H30O2S

Molecular Weight

358.54

Precautions

H302, H315, H319, H335

References & Citations

[1]Makovski V, et al. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis. Int J Cancer. 2012 Mar 15;130 (6) :1420-9.|[2]Nevo Y, et al. Chapman J. The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy. PLoS One. 2011 Mar 22;6 (3) :e18049.|[3]Charette N, et al. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol Cancer. 2010 Sep 22;9:256.